Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings.

Perrotta FM, Scriffignano S, De Socio A, Lubrano E.

Rheumatol Ther. 2019 Mar;6(1):125-133. doi: 10.1007/s40744-019-0145-7. Epub 2019 Feb 6.

2.

Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting.

Lubrano E, Scriffignano S, De Socio A, Perrotta FM.

Clin Exp Rheumatol. 2018 Dec 20. [Epub ahead of print] No abstract available.

PMID:
30620284
3.

Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement.

Marchesoni A, D'Angelo S, Anzidei M, Bortolotti R, Cantini F, Caramella D, Carotti M, Chimenti MS, Delle Sedie A, Egan CG, Fabbroni M, Frediani B, Fusaro E, Galeazzi M, Gallazzi MB, Gentileschi S, Gentili F, Gerli R, Gilio M, Iannone F, La Paglia E, Lubrano E, Macarini L, Olivieri I, Pellerito R, Ramonda R, Salvarani C, Scarano E, Scarpa R, Spaggiari L, Spanò A, Zawaideh JP, Mazzei MA; SHARE Study Group.

Clin Exp Rheumatol. 2018 Nov 16. [Epub ahead of print]

PMID:
30557127
4.

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis.

Felice C, Leccese P, Scudeller L, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Olivieri I, Armuzzi A; Italian SpA-IBD Expert Panel Group.

Clin Exp Immunol. 2019 Apr;196(1):123-138. doi: 10.1111/cei.13246. Epub 2019 Jan 9.

PMID:
30554407
5.

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.

Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L.

Ann Rheum Dis. 2019 Feb;78(2):201-208. doi: 10.1136/annrheumdis-2018-214140. Epub 2018 Nov 15.

PMID:
30442648
6.

Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Scriffignano S, Perrotta FM, De Socio A, Lubrano E.

Clin Rheumatol. 2019 Jan;38(1):3-10. doi: 10.1007/s10067-018-4332-7. Epub 2018 Oct 18.

PMID:
30338414
7.

Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature.

Ruscitti P, Sinigaglia L, Cazzato M, Grembiale RD, Triolo G, Lubrano E, Montecucco C, Giacomelli R.

Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii23-vii31. doi: 10.1093/rheumatology/key132. Review.

PMID:
30289540
8.

Generalized anhidrosis as first clinical presentation of systemic lupus erythematosus.

Provitera V, Lubrano E, Piscosquito G, Manganelli F, Santoro L, Nolano M.

Lupus. 2018 Dec;27(14):2296-2297. doi: 10.1177/0961203318804887. Epub 2018 Oct 3. No abstract available.

PMID:
30282559
9.

Abatacept for the treatment of psoriatic arthritis.

Lubrano E, Scriffignano S, Perrotta FM.

Expert Rev Clin Immunol. 2018 Nov;14(11):899-905. doi: 10.1080/1744666X.2018.1527218. Epub 2018 Oct 12.

PMID:
30246575
10.

What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?

Coates LC, Lubrano E, Perrotta FM, Emery P, Conaghan PG, Helliwell PS.

J Rheumatol. 2019 Jan;46(1):38-42. doi: 10.3899/jrheum.180267. Epub 2018 Sep 15.

PMID:
30219765
11.

Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis.

Scriffignano S, Perrotta FM, De Socio A, Altobelli A, Sessa P, Scrivo R, Valesini G, Lubrano E.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):193-198. Epub 2018 Aug 29.

PMID:
30183600
12.

Clinical implications of peripheral new bone formation in psoriatic arthritis: a literature-based review.

Marchesoni A, Caporali R, Lubrano E.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):310-317. Epub 2018 Aug 29. Review.

PMID:
30183592
13.

Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement.

Olivieri I, Accorinti M, Abicca I, Bisceglia P, Cimino L, Latanza L, Leccese P, Lubrano E, Marchesoni A, Miserocchi E, Neri P, Salvarani C, Scarpa R, D'Angelo S; CORE Study Group.

Rheumatol Int. 2018 Sep;38(9):1727-1734. doi: 10.1007/s00296-018-4094-1. Epub 2018 Jun 30.

PMID:
29961101
14.

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Aug;45(9):1256-1262. doi: 10.3899/jrheum.171183. Epub 2018 Jun 15.

PMID:
29907666
15.

Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.

Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, De Socio A, Scriffignano S, Alessandri C, Lubrano E.

J Immunol Res. 2018 May 2;2018:9101964. doi: 10.1155/2018/9101964. eCollection 2018.

16.

Clinical remission in rheumatoid arthritis and psoriatic arthritis.

Lubrano E, Mesina F, Caporali R.

Clin Exp Rheumatol. 2018 Sep-Oct;36(5):900-910. Epub 2018 Mar 16. Review.

17.

Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease.

Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D'Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G.

Adv Ther. 2018 Apr;35(4):545-562. doi: 10.1007/s12325-018-0672-6. Epub 2018 Mar 7.

18.

Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.

Perrotta FM, De Socio A, Scriffignano S, Lubrano E.

Clin Rheumatol. 2018 Jun;37(6):1449-1455. doi: 10.1007/s10067-018-4038-x. Epub 2018 Feb 21.

PMID:
29468339
19.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.

Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2018 Feb;45(2):195-201. doi: 10.3899/jrheum.170666.

PMID:
29419448
20.

From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications.

Perrotta FM, De Socio A, Scriffignano S, Lubrano E.

Expert Rev Clin Immunol. 2018 Mar;14(3):207-213. doi: 10.1080/1744666X.2018.1429918. Epub 2018 Jan 25. Review.

PMID:
29338498
21.

Consensus on the management of patients with psoriatic arthritis in a dermatology setting.

Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, Foti C, Idolazzi L, Lubrano E, Malara G, Marchesoni A, Olivieri I, Parodi A, Peris K, Piaserico S, Salvarani C, Scarpa R, Girolomoni G.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):515-528. doi: 10.1111/jdv.14741. Epub 2018 Jan 11.

PMID:
29220551
22.

Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.

Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D'Angelo S, Mathieu A, Cauli A, Punzi L, Ramonda R, Scarpa R, Maccarone M, Lubrano E.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):991-1010. Epub 2017 Nov 28.

PMID:
29185959
23.

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.

Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2017 Nov 15. pii: jrheum.17666. doi: 10.3899/jrheum.17666. [Epub ahead of print]

PMID:
29142035
24.

Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.

Gossec L, McGonagle D, Korotaeva T, Lubrano E, de Miguel E, Østergaard M, Behrens F.

J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15. Review.

25.

Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study.

De Socio A, Perrotta FM, Grasso GM, Lubrano E.

Postgrad Med. 2018 Jan;130(1):137-141. doi: 10.1080/00325481.2018.1399774. Epub 2017 Nov 3.

PMID:
29088976
26.

Psoriatic arthritis: is it time to treat-to-target or target to treat?

Lubrano E, Perrotta FM.

Clin Rheumatol. 2017 Dec;36(12):2633-2635. doi: 10.1007/s10067-017-3885-1. Epub 2017 Oct 24.

PMID:
29067586
27.

Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts.

Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I; Italian SpA-IBD Expert Panel Group.

Dig Liver Dis. 2017 Dec;49(12):1298-1305. doi: 10.1016/j.dld.2017.06.004. Epub 2017 Jun 23. Review.

PMID:
28822731
28.

Unmet Needs in Axial Spondyloarthritis.

Lubrano E, De Socio A, Perrotta FM.

Clin Rev Allergy Immunol. 2018 Dec;55(3):332-339. doi: 10.1007/s12016-017-8637-0. Review.

PMID:
28779298
29.

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management.

Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, Carubbi F, Cauli A, Cervera R, Ciccia F, Cipriani P, Conti F, De Vita S, Di Benedetto P, Doria A, Drosos AA, Favalli EG, Gandolfo S, Gatto M, Grembiale RD, Liakouli V, Lories R, Lubrano E, Lunardi C, Margiotta DPE, Massaro L, Meroni P, Minniti A, Navarini L, Pendolino M, Perosa F, Pers JO, Prete M, Priori R, Puppo F, Quartuccio L, Ruffatti A, Ruscitti P, Russo B, Sarzi-Puttini P, Shoenfeld Y, Somarakis GA, Spinelli FR, Tinazzi E, Triolo G, Ursini F, Valentini G, Valesini G, Vettori S, Vitali C, Tzioufas AG.

Autoimmun Rev. 2017 Sep;16(9):911-924. doi: 10.1016/j.autrev.2017.07.012. Epub 2017 Jul 11. Review.

PMID:
28705780
30.

Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.

Costa L, Lubrano E, Ramonda R, Chimenti MS, Vezzù M, Perrotta FM, Del Puente A, Peluso R, Bottiglieri P, Lorenzin M, Sunzini F, Darda MA, Fiocco U, Perricone R, Punzi L, Scarpa R, Caso F.

Clin Rheumatol. 2017 Aug;36(8):1797-1802. doi: 10.1007/s10067-017-3697-3. Epub 2017 Jun 7.

PMID:
28589323
31.

Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.

Lubrano E, De Socio A, Perrotta FM.

J Rheumatol. 2017 Aug;44(8):1159-1164. doi: 10.3899/jrheum.170112. Epub 2017 Jun 1.

PMID:
28572467
32.

Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis.

Perrotta FM, Guerra G, De Socio A, Scriffignano S, Lubrano E.

Reumatismo. 2017 May 22;69(1):1-8. doi: 10.4081/reumatismo.2017.976. Review.

33.

The role of IL-17 in the treatment of psoriatic arthritis.

Lubrano E, Perrotta FM.

Expert Rev Clin Immunol. 2017 Aug;13(8):815-821. doi: 10.1080/1744666X.2017.1327354. Epub 2017 May 16.

PMID:
28485176
34.

Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report.

Perrotta FM, Fici M, Guerra G, Brunese L, Salvarani C, Lubrano E.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):226-227. Epub 2017 Apr 20. No abstract available.

PMID:
28466807
35.

Secukinumab for ankylosing spondylitis and psoriatic arthritis.

Lubrano E, Perrotta FM.

Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592. eCollection 2016. Review.

36.

Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients.

Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, Montepaone M, Alessandri C, Valesini G, Lubrano E.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):313-316. Epub 2016 Oct 26.

PMID:
27782869
37.

New approved drugs for psoriatic arthritis.

Perrotta FM, Lubrano E.

Reumatismo. 2016 Sep 9;68(2):57-64. doi: 10.4081/reumatismo.2016.873. Review. Italian.

38.

A national survey on the management of psoriatic arthritis using the Delphi method.

Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):214-220. Epub 2016 Aug 31.

PMID:
27607572
39.

An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment.

Perrotta FM, Astorri D, Zappia M, Reginelli A, Brunese L, Lubrano E.

Rheumatol Int. 2016 Nov;36(11):1579-1583. Epub 2016 Sep 6.

PMID:
27600991
40.

Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments.

Lubrano E, Perrotta FM.

J Rheumatol. 2016 Sep;43(9):1765-6. doi: 10.3899/jrheum.160386. No abstract available.

PMID:
27587014
41.

Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.

Perrotta FM, Lubrano E.

Postgrad Med. 2016 Sep;128(7):693-6. doi: 10.1080/00325481.2016.1220809. Epub 2016 Aug 16.

PMID:
27494077
42.

Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists.

Marchesoni A, Lubrano E, Manara M, Ramonda R, Salvarani C, Olivieri I.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1051-1058. Epub 2016 Jul 26.

PMID:
27462870
43.

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.

Lubrano E, Massimo Perrotta F, Manara M, D'Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A.

J Rheumatol. 2016 Aug;43(8):1541-6. doi: 10.3899/jrheum.160363. Epub 2016 Jun 1. Erratum in: J Rheumatol. 2016 Sep;43(9):1772.

PMID:
27252428
44.

Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.

Lubrano E, Parsons WJ, Perrotta FM.

J Rheumatol. 2016 May;43(5):918-23. doi: 10.3899/jrheum.151404. Epub 2016 Mar 15.

PMID:
26980581
45.

Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.

Lubrano E, Perrotta FM.

Drugs. 2016 Apr;76(6):663-73. doi: 10.1007/s40265-016-0557-4. Review.

PMID:
26957495
46.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT.

Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.

47.

Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.

Perrotta FM, Marchesoni A, Lubrano E.

J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.

PMID:
26669925
48.

Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.

Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3.

PMID:
26633622
49.

Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.

Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L.

Expert Rev Clin Immunol. 2016;12(3):315-31. doi: 10.1586/1744666X.2016.1117941. Epub 2015 Dec 9. Review.

PMID:
26558483
50.

New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.

Cauli A, Piga M, Lubrano E, Marchesoni A, Floris A, Mathieu A.

J Rheumatol Suppl. 2015 Nov;93:70-2. doi: 10.3899/jrheum.150641. Review.

PMID:
26523062

Supplemental Content

Loading ...
Support Center